AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00900159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: eszopiclone
Description: 3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
Study NCT00900159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
Study NCT02851589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCAR-019 (anti-CD19 CAR-T cells)
Study NCT04373759 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary resuscitation
Description: Cardiopulmonary resuscitation
Study NCT04373759 — intervention group
Intervention type: OTHER
Intervention: Modified Rankin score
Description: 0 - no symptoms at all~1. - no significant disability despite symptoms; able to carry out all usual duties and activities~2. - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance~3. - Moderate disability; requiring some help, but able to walk without assistance~4. - Moderately severe disability; unable to walk and attend to bodily needs without assistance~5. - Severe disability; bedridden, incontinent and requiring constant nursing care and attention~6. - Dead
Study NCT03529955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).
Study NCT02460848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient therapeutic program, counseling and cash transfer
Description: Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.~The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption.
Study NCT02460848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient therapeutic program and counseling
Study NCT04901000 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Carotid endarterectomy prior to CABG operations either under Local Anaesthetic or under General Anaesthetic.
Study NCT03086356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Days 1-4 and Day 8-11
Study NCT03086356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Description: Day 11
Study NCT03303638 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multi-sensory Environment
Description: Multi-sensory environments (MSE), also known as Snoezelen® environments, are defined as behavioral environmental intervention to help people with cognitive and physical impairments reach sensory equilibrium. Typical elements within MSE include visual, auditory, tactile and olfactory stimuli, ergonomic vibro-acoustic furniture, bubble tubes, color-changing LED lighting solutions, music, fiber optics and aromatherapy.
Study NCT03322514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Inulin
Study NCT02992405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS Resilience Enhancement Program
Description: Each couple or family will have 10 weekly 75 minute sessions comprising the treatment protocol.Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the 10-week treatment is completed (T2).
Study NCT02992405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waitlist (No Study Treatment)
Description: Participants assigned to the Waitlist (No Treatment) group will receive the study intervention only after the 10 weeks of the immediate treatment phase has been completed. Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the immediate treatment phase is completed (T2).
Study NCT01842958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straumann Bone Level Implants, 4.1 mm implant diameter
Description: Straumann Bone Level Implants, 4.1 mm implant diameter
Study NCT01842958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straumann Bone Level Implants, 3.3 mm implant diameter
Description: Straumann Bone Level Implants, 3.3 mm implant diameter
Study NCT02474290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Study NCT03476187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: µCor
Description: Monitor with µCor
Study NCT04093570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 film-coated, immediate-release FDC tablets
Study NCT00747370 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: movement of midurethra, bladder neck, cervix and rectum
Study NCT03937128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training
Description: Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout the training.
Study NCT03937128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
Study NCT03937128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as usual
Description: Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
Study NCT03715478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2857916 with Pomalidomide and Dexamethasone
Description: Recommended phase 2 dose (RP2D) of GSK2857916 determined by the phase 1 portion of study will be administered in combination with pomalidomide (approved dose and schedule) and dexamethasone until progression of disease.
Study NCT03556839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous Infusion
Study NCT03556839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenous Infusion
Study NCT03556839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous Infusion
Study NCT03556839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/Carboplatin
Description: Intravenous Infusion
Study NCT03556839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: Intravenous Infusion
Study NCT03556839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous Infusion
Study NCT03556839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous Infusion
Study NCT01105923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAPLE
Description: MAPLE is a CDS intervention within the EHR that will alert providers to problem lists gaps and present an opportunity to correct them.
Study NCT02122705 — intervention group
Intervention type: DEVICE
Intervention: VPIA remifentanil
Description: Vital signs controlled patient assisted intravenous analgesia using remifentanil
Study NCT05712213 — intervention group
Intervention type: PROCEDURE
Intervention: Intraperitoneal onlay mesh reinforcement with defect closure before placement of mesh (pIPOM)
Description: The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. The laparoscopic closure of the hernia defect was performed with non-reabsorbable detached stitches of prolene 1/0 suture at a distance of 1.5 cm from stich to stich using a Reverdin' needle. The final fixation of the mesh took place with a non-resorbable tacks.
Study NCT05712213 — intervention group
Intervention type: PROCEDURE
Intervention: Standard intraperitoneal onlay mesh repair (sIPOM)
Description: The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. In sIPOM, the defect was not closed. The final fixation of the mesh took place with a non-resorbable tacks.
Study NCT04251793 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Soft tissue implant measurements and radiographs
Study NCT02125786 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation
Description: Radiation therapy on this protocol will be based on extent of disease, extent of resection and location. The allowed treatment modalities include conformal or intensity-modulated radiation therapy using photons or proton therapy using double-scattering or spot-scanning methods. The general goal is to initiate radiation therapy within 12 weeks of last surgery performed at the time of recurrence.
Study NCT02125786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: When applicable, surgery will be used to remove metastases. The goal of surgery is to achieve gross total resection of all imaging visible residual tumor.
Study NCT02125786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ^1^8F-Fluorodeoxyglucose
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Study NCT02125786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ^1^1C-methionine
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Study NCT02125786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photon therapy
Description: Participants will receive one or both: Photon or proton therapy.
Study NCT02125786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton therapy
Description: Participants will receive one or both: Photon or proton therapy.
Study NCT02002455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT, PET/MRI, mpMRI
Description: FACBC dose 370 megabecquerel (MBq)
Study NCT03306082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image-Guided Cochlear Implant Programming
Description: Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
Study NCT04035434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX110
Description: CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
Study NCT05119387 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation of genetic characteristics
Study NCT03119350 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Training
Description: Intervention with concurrent physical training: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation to physical exercise, 8 weeks of training. Frequency: 3 times a week. Time: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate.
Study NCT02259192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED-EL Maestro Cochlear Implant
Description: cochlear implant
Study NCT00049166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT06251752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X-rays: load bearing inferior limbs, lateral knee, axial patella
Description: X-rays at 5 years follow-up minimum
Study NCT05125575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
Description: One tablet of the Test (T) product was administered orally with 240 mL of water.
Study NCT05125575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 1000 mg Prolonged Release Tablets
Description: One tablet of the Reference (R) product was administered orally with 240 mL of water.
Study NCT02701127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral niacinamide, 1 gram daily
Study NCT02701127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral niacinamide, 3 gram daily
Study NCT00049166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00916890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
Study NCT00916890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
Study NCT00916890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
Study NCT00049166 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo intensity modulated radiation therapy
Study NCT00049166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00916890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
Study NCT01983020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT01983020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT01983020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02217410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533
Study NCT02217410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Study NCT02217410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Tac)
Study NCT02217410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Study NCT01909466 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole, OPC-14597
Description: 5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
Study NCT02217410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Study NCT02217410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Study NCT02217410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (CS)
Study NCT02775890 — intervention group
Intervention type: BEHAVIORAL
Intervention: Eating wild game shot with lead bullets
Description: Participants will eat meat harvested with lead bullets, prepare mince meat and eat at least a standard serving (>85 grams).
Study NCT04693065 — intervention group
Intervention type: OTHER
Intervention: ponseti
Description: Standard of care, treatment by ponseti method
Study NCT02217410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-IL2 Induction
Study NCT02217410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: anti-IL2 Induction
Study NCT02907528 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bone
Description: Furcation defect regenerated with bone graft material
Study NCT02780557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent Reading Intervention
Description: Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.
Study NCT02780557 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Book Provision Control
Description: Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
Study NCT03931096 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: Self and proxy PedsQL 4.0 questionnaires.
Study NCT04050397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive supervised weight training
Description: 12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.
Study NCT04050397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.
Study NCT04050397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lecture
Description: Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.
Study NCT03090984 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMMA (BKU)
Description: At serial time points before, during and after each study hemodialysis session using a BKU dialyzer, blood samples will be drawn for coagulation activation analyses.
Study NCT03090984 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS (Phylter)
Description: At serial time points before, during and after each study hemodialysis session using a Phylter dialyzer, blood samples will be drawn for coagulation activation
Study NCT03090984 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AN69ST (Evodial)
Description: At serial time points before, during and after each study hemodialysis session using an Evodial dialyzer, blood samples will be drawn for coagulation activation
Study NCT00274209 — intervention group
Intervention type: PROCEDURE
Intervention: Chromoendoscopy with magnification
Description: A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
Study NCT02473978 — intervention group
Intervention type: DEVICE
Intervention: INVOS Cerebral Oximetry
Description: Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
Study NCT04050488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulfate
Description: At the age of 3 days or priming> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
Study NCT04050488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: At the age of 3 days or priming> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
Study NCT03089528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy
Description: the trachea will be intubated with a videolaryngoscope